{
  "title": "Predicting Response to Intravesical Bacillus Calmette-Gu\u00e9rin in High-Risk Nonmuscle-Invasive Bladder Cancer Using an Artificial Intelligence\u2013Powered Pathology Assay: Development and Validation in an International 12-Center CohortEditorial Comment.Bladder cancer: a reviewDiagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guidelineEuropean Association of Urology guidelines on non-muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ)NCCN Guidelines Insights: bladder cancer, version 2.2022Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guerin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenanceCritical shortage in BCG immunotherapy: how did we get here and where will it take us?Background and update for ECOG-ACRIN EA8212: a randomized phase 3 trial of intravesical Bacillus Calmette-Guerin (BCG) versus intravesical docetaxel and gemcitabine treatment in BCG-naive high-grade non-muscle-invasive bladder cancer (BRIDGE)DLBCL-Morph: morphological features computed using deep learning for an annotated digital DLBCL image setDevelopment of an artificial intelligence-derived histologic signature associated with adjuvant gemcitabine treatment outcomes in pancreatic cancerREporting recommendations for tumour MARKer prognostic studies (REMARK)Validation of biomarker-based risk prediction modelsDefinitions, end points, and clinical trial designs for bladder cancer: recommendations from the society for immunotherapy of cancer and the International Bladder Cancer GroupDefining progression in nonmuscle invasive bladder cancer: it is time for a new, standard definitionOpenSlide: a vendor-neutral software foundation for digital pathologyEuropean Association of Urology (EAU) prognostic factor risk groups for non-muscle-invasive bladder cancer (NMIBC) incorporating the WHO 2004/2016 and WHO 1973 classification systems for grade: an update from the EAU NMIBC guidelines panelEORTC nomograms and risk groups for predicting recurrence, progression, and disease-specific and overall survival in non-muscle-invasive stage Ta-T1 urothelial bladder cancer patients treated with 1-3 years of maintenance Bacillus Calmette-GuerinAccuracy of the CUETO, EORTC 2016 and EAU 2021 scoring models and risk stratification tables to predict outcomes in high-grade non-muscle-invasive urothelial bladder cancerAccuracy of the EORTC risk tables and of the CUETO scoring model to predict outcomes in non-muscle-invasive urothelial carcinoma of the bladderMarkers predicting response to bacillus Calmette-Guerin immunotherapy in high-risk bladder cancer patients: a systematic reviewRisk prediction scores for recurrence and progression of non-muscle invasive bladder cancer: an international validation in primary tumoursValidation of EORTC, CUETO, and EAU risk stratification in prediction of recurrence, progression, and death of patients with initially non-muscle-invasive bladder cancer (NMIBC): a cohort analysisUpdated European Association of Urology (EAU) prognostic factor risk groups overestimate the risk of progression in patients with non-muscle-invasive bladder cancer treated with Bacillus Calmette-GuerinBladder cancer prognosis using deep neural networks and histopathology imagesDifferentiation of urothelial carcinoma in histopathology images using deep learning and visualizationMultiresolution application of artificial intelligence in digital pathology for prediction of positive lymph nodes from primary tumors in bladder cancerUnlocking the potential of adequate Bacillus Calmette-Guerin immunotherapy in very-high-risk non-muscle-invasive bladder carcinoma: a multicenter analysis of oncological outcomes and risk dynamicsComparison of sequential intravesical gemcitabine and docetaxel vs Bacillus Calmette-Guerin for the treatment of patients with high-risk non-muscle-invasive bladder cancerElectromotive drug administration (EMDA) of mitomycin C as first-line salvage therapy in high risk \u201cBCG failure\u201d non muscle invasive bladder cancer: 3 years follow-up outcomesLong-term follow-up of sequential intravesical gemcitabine and docetaxel salvage therapy for non-muscle invasive bladder cancer",
  "pmcid": "12674634",
  "features": {
    "sample_size": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "randomization": {
      "present": true,
      "count": 1,
      "unique_matches": [
        "allocation"
      ],
      "examples": [
        {
          "match": "Allocation",
          "context": "ity, and immune infiltration. Allocation of an international, multi-in"
        }
      ]
    },
    "blinding": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "allocation_concealment": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "interaction_subgroup": {
      "present": true,
      "count": 2,
      "unique_matches": [
        "stratification"
      ],
      "examples": [
        {
          "match": "stratification",
          "context": "2021 scoring models and risk stratification tables to predict outcomes in"
        },
        {
          "match": "stratification",
          "context": "of EORTC, CUETO, and EAU risk stratification in prediction of recurrence,"
        }
      ]
    },
    "variable_definitions": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "analysis_principles": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "itt_details": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "software": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "error_measures": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "multiplicity_correction": {
      "present": true,
      "count": 2,
      "unique_matches": [
        "no adjustment",
        "adjustment for multiplicity"
      ],
      "examples": [
        {
          "match": "adjustment for multiplicity",
          "context": "EAU 2021 risk models.15,16 No adjustment for multiplicity of testing the recurrence-fre"
        },
        {
          "match": "No adjustment",
          "context": "nd EAU 2021 risk models.15,16 No adjustment for multiplicity of testing t"
        }
      ]
    },
    "normality_checks": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "p_values": {
      "present": true,
      "count": 1,
      "unique_matches": [
        "secondary end point"
      ],
      "examples": [
        {
          "match": "Secondary end point",
          "context": "uscle invasion (\u2265T2 stage).13 Secondary end points were cystectomy-free surviva"
        }
      ]
    },
    "confidence_intervals": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "comparative_stats": {
      "present": true,
      "count": 3,
      "unique_matches": [
        "wilcoxon",
        "\u03c72"
      ],
      "examples": [
        {
          "match": "\u03c72",
          "context": "ponding likelihood ratio (LR) \u03c72 statistics to test the null h"
        },
        {
          "match": "\u03c72",
          "context": "isher exact test, and Pearson \u03c72 test.Bolded text represents s"
        },
        {
          "match": "Wilcoxon",
          "context": "y. Groups were compared using Wilcoxon rank-sum test, Fisher exact t"
        }
      ]
    },
    "non_parametric": {
      "present": true,
      "count": 1,
      "unique_matches": [
        "bootstrapping"
      ],
      "examples": [
        {
          "match": "bootstrapping",
          "context": "based on additive regression, bootstrapping, and predictive mean matching"
        }
      ]
    },
    "advanced_modeling": {
      "present": true,
      "count": 1,
      "unique_matches": [
        "bootstrapping"
      ],
      "examples": [
        {
          "match": "bootstrapping",
          "context": "based on additive regression, bootstrapping, and predictive mean matching"
        }
      ]
    },
    "assumption_checks": {
      "present": true,
      "count": 1,
      "unique_matches": [
        "proportional hazards"
      ],
      "examples": [
        {
          "match": "proportional hazards",
          "context": "ictive model development. Cox proportional hazards (CPH) regression was used to"
        }
      ]
    },
    "survival_analysis": {
      "present": true,
      "count": 9,
      "unique_matches": [
        "log-rank",
        "rfs",
        "overall survival",
        "kaplan-meier"
      ],
      "examples": [
        {
          "match": "Kaplan-Meier",
          "context": "parametric maximum likelihood Kaplan-Meier estimates of survival stratif"
        },
        {
          "match": "log-rank",
          "context": "gh-risk groups and associated log-rank tests for each clinical end p"
        },
        {
          "match": "RFS",
          "context": "e recurrence-free survival (hgRFS) and progression-free surviva"
        }
      ]
    },
    "regression_and_models": {
      "present": true,
      "count": 1,
      "unique_matches": [
        "cox proportional"
      ],
      "examples": [
        {
          "match": "Cox proportional",
          "context": "predictive model development. Cox proportional hazards (CPH) regression was"
        }
      ]
    },
    "reporting_guidelines": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "data_types": {
      "present": true,
      "count": 6,
      "unique_matches": [
        "binary",
        "continuous",
        "proportions"
      ],
      "examples": [
        {
          "match": "continuous",
          "context": "atures based on the resulting continuous linear predictor from the CPH"
        },
        {
          "match": "continuous",
          "context": "ts. Medians and IQRs for each continuous clinical characteristic were"
        },
        {
          "match": "binary",
          "context": "s. Counts and proportions for binary clinical characteristics and"
        }
      ]
    },
    "dependency": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "clustering": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "missing_data": {
      "present": true,
      "count": 2,
      "unique_matches": [
        "missing data",
        "complete case"
      ],
      "examples": [
        {
          "match": "missing data",
          "context": "spectively. In the EV cohort, missing data were imputed to allow for app"
        },
        {
          "match": "Complete case",
          "context": "and predictive mean matching. Complete case analyses using casewise delet"
        }
      ]
    },
    "effect_size": {
      "present": true,
      "count": 5,
      "unique_matches": [
        "rr",
        "hr"
      ],
      "examples": [
        {
          "match": "HR",
          "context": "er) with primary or recurrent HR-NMIBC per AUA criteria diagno"
        },
        {
          "match": "HR",
          "context": "tients treated for high-risk (HR) nonmuscle-invasive bladder c"
        },
        {
          "match": "HR",
          "context": "the null hypothesis that the HR for each (binary) AI model wa"
        }
      ]
    },
    "post_hoc": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "baseline_reporting": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "advanced_modeling_extra": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "systematic_review_metrics": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "diagnostic_metrics": {
      "present": true,
      "count": 1,
      "unique_matches": [
        "nomogram"
      ],
      "examples": [
        {
          "match": "nomogram",
          "context": "U NMIBC guidelines panelEORTC nomograms and risk groups for predicti"
        }
      ]
    },
    "model_details": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "domain_indicators": {
      "present": true,
      "count": 1,
      "unique_matches": [
        "immunohistochemistry"
      ],
      "examples": [
        {
          "match": "immunohistochemistry",
          "context": "ction, H&E slides with paired immunohistochemistry (CD68) were used to identify"
        }
      ]
    }
  },
  "feedback": {
    "overall_score": 5.5,
    "rigor_rating": "Medium",
    "critical_gaps": [
      {
        "message": "Explicitly stated that no multiplicity correction or formal hypothesis testing was performed.",
        "evidence": "...EAU 2021 risk models.15,16 No adjustment for multiplicity of testing the recurrence-fre..."
      },
      {
        "message": "Missing data handeld via complete-case analysis (potential bias).",
        "evidence": "...spectively. In the EV cohort, missing data were imputed to allow for app..."
      },
      {
        "message": "Categorical data mentioned, but no appropriate categorical tests found.",
        "evidence": "...atures based on the resulting continuous linear predictor from the CPH..."
      }
    ],
    "strengths": [
      {
        "message": "Analysis context identifies basic science or bioinformatics (Softened clinical trial requirements).",
        "evidence": "Detected term: 'immunohistochemistry'"
      },
      {
        "message": "Reported effect sizes (e.g., OR, HR, MD) alongside statistical significance.",
        "evidence": "...er) with primary or recurrent HR-NMIBC per AUA criteria diagno..."
      },
      {
        "message": "Verified proportional hazards assumption.",
        "evidence": "...ictive model development. Cox proportional hazards (CPH) regression was used to..."
      },
      {
        "message": "Reported diagnostic metrics (AUC/ROC).",
        "evidence": "...U NMIBC guidelines panelEORTC nomograms and risk groups for predicti..."
      }
    ],
    "actionable_recommendations": [
      {
        "item": "Multiplicity",
        "issue": "Lack of correction increases Type I error.",
        "recommendation": "Use Bonferroni or FDR, or label as exploratory.",
        "source_text": "no adjustment adjustment for multiplicity"
      }
    ],
    "deterministic_audit": true
  }
}